Feeds:
Posts
Comments

2018 National Academy of Sciences AWARDS on April 29 during the Academy’s 155th annual meeting

February 8, 2018 by 2012pharmaceutical

2018 National Academy of Sciences AWARDS on April 29 during the Academy’s 155th annual meeting

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #251: 2018 National Academy of Sciences AWARDS on April 29 during the Academy’s 155th annual meeting. Published on 2/8/2018

WordCloud Image Produced by Adam Tubman

The National Academy of Sciences will honor the following individuals with awards in recognition of their extraordinary scientific achievements in a wide variety of fields. These awards will be presented to on April 29 during the Academy’s 155th annual meeting.

NAS Public Welfare Medal
Paul Farmer
For pioneering enduring, community-based treatment strategies that demonstrate the delivery of high-quality health care in resource-poor settings in the U.S. and other countries.

The NAS Public Welfare Medal is the Academy’s most prestigious award and is presented annually to honor extraordinary use of science for the public good.

Alexander Agassiz Medal
Dean Roemmich
For his leadership in understanding the ocean’s roles in climate variability and change.

Atkinson Prize in Psychological and Cognitive Sciences
Barbara Dosher
For her groundbreaking work on human memory, attention, and learning.

Atkinson Prize in Psychological and Cognitive Sciences
Richard M. Shiffrin
For pioneering contributions to the investigation of memory and attention.

Daniel Giraud Elliot Medal
Günter Wagner
For his book “Homology, Genes, and Evolutionary Innovation,” which makes fundamental contributions to our understanding of the evolution of complex organisms.

Gilbert Morgan Smith Medal
Mark E. Hay
For his research into algal science, with implications for the world’s imperiled coral reefs.

J. Lawrence Smith Medal
Kevin D. McKeegan
For discoveries related to the oxygen isotopic composition of the sun.

James Craig Watson Medal
Ewine F. van Dishoeck
For improving our understanding of how molecules, stars, and planets form.

Jessie Stevenson Kovalenko Medal
James P. Allison
For important medical discoveries related to the body’s immune response to tumors.

John J. Carty Award for the Advancement of Science
David M. Kreps, Paul R. Milgrom, Robert B. Wilson
For using game theory to help solve real-world problems.

Michael and Sheila Held Prize
Prasad Raghavendra and David Steurer
For revolutionizing our understanding of optimization and complexity in computer science.

NAS Award for Scientific Reviewing
Adriaan Bax
For contributions that have greatly impacted the field of structural biology.

NAS Award in Chemical Sciences
Jennifer A. Doudna
For co-inventing the technology for efficient site-specific genome engineering using CRISPR/Cas9 nucleases.

NAS Award in Molecular Biology
Howard Y. Chang
For the discovery of long noncoding RNAs and the invention of genomic technologies.

NAS Prize in Food and Agriculture Sciences
Rodolphe Barrangou
For his discovery of the genetic mechanisms and proteins driving CRISPR-Cas systems.

Pradel Research Award
Silvia Arber
For her groundbreaking research on the organization and function of circuits regulating motor behavior.

Troland Research Award
Marlene R. Cohen
For her pioneering studies of how neurons in the brain process visual information.

Troland Research Award
Josh McDermott
For groundbreaking research into how humans hear and interpret sound.

William and Katherine Estes Award
Etel Solingen
For pathbreaking work on nuclear proliferation and reducing the risks of nuclear war.

SOURCE

http://www.nasonline.org/programs/awards/2018-awards.html?referrer=http://news.berkeley.edu/story_jump/national-academy-of-sciences-honors-raghavendra-doudna/

Posted in National Academy of Sciences AWARDS | Leave a Comment »

National Academy of Sciences for work in chemical sciences: Jennifer Doudna, University of California, Berkeley

February 8, 2018 by 2012pharmaceutical

National Academy of Sciences for work in chemical sciences: Jennifer Doudna, University of California, Berkeley

Reporter: Aviva Lev-Ari, PhD, RN

National Academy of Sciences awards for Raghavendra, Doudna

ByRobert Sanders, Media relations |

2.1.5.3

2.1.5.3   National Academy of Sciences for work in chemical sciences: Jennifer Doudna, University of California, Berkeley, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Prasad Raghavendra and Jennifer Doudna received awards this week from the National Academy of Sciences for work incomputer science and chemical sciences, respectively.

Prasad Raghavendra, an associate professor of electrical engineering and computer science, and Jennifer Doudna, a professor of molecular and cell biology and of chemistry, were honored this week by the National Academy of Sciences for their innovative body of research.

Raghavendra shared the inaugural Michael and Sheila Held Prize with David Steurer, a professor of theoretical computer science at ETH Zurich, for “revolutionary contributions to the understanding of optimization and complexity in computer science, work that has relevance for solving the most difficult and intractable of computing problems.” The winners will share the $100,000 prize.

Doudna, a Howard Hughes Medical Institute investigator, received the 2018 NAS Award in Chemical Sciences for “pioneering discoveries on how RNA can fold to function in complex ways” and the invention, with Emmanuelle Charpentier, of the CRISPR-Cas9 gene-editing technology.

The winners will be honored in a ceremony on Sunday, April 29, during the National Academy of Sciences’ 155th annual meeting.

Raghavendra’s prize, awarded this year for the first time, was made possible through a bequest from the estate of Michael and Sheila Held. Doudna’s award, established in 1978 and currently supported by the Merck Company Foundation, is accompanied by a medal and a $15,000 prize.

Previous winners of the NAS Award in Chemical Sciences include Paul Alivisatos, a professor of chemistry and UC Berkeley’s executive vice chancellor and provost, chemistry professors emeritus Gabor Somorjai and Robert Bergman, and former chemistry professor Carolyn Bertozzi, who is now at Stanford University.

Another former UC Berkeley faculty member, James Allison, received the NAS’s 2018 Jessie Stevenson Kovalenko Medal “for important medical discoveries related to the body’s immune response to tumors.” He is now at the University of Texas MD Anderson Cancer Center. All are among 18 awards to 21 scientists announced this week.

National Academy of Sciences announcement
SOURCE

SOURCE 

TED.com

Posted in CRISPR/Cas9 & Gene Editing | Leave a Comment »

Relations between Breast Cancer and DIET: amino acid called asparagine

February 8, 2018 by 2012pharmaceutical

Relations between Breast Cancer and DIET: amino acid called asparagine

Reporter: Aviva Lev-Ari, PhD, RN

 

 

Diet may influence the spread of a deadly type of breast cancer, study finds

February 7, 2018, Cedars-Sinai Medical Center
Diet may influence the spread of a deadly type of breast cancer, study finds
Three-dimensional cell culture of breast cancer cells. Credit: National Institutes of Health (Dao Tiensinh)

A single protein building block commonly found in food may hold a key to preventing the spread of an often-deadly type of breast cancer, according to a new multicenter study published today in the medical journal Nature.

Investigators found that by limiting an amino acid called asparagine in laboratory mice with triple-negative breast cancer, they could dramatically reduce the ability of the cancer to travel to distant sites in the body. Among other techniques, the team used dietary restrictions to limit asparagine.

Foods rich in asparagine include dairy, whey, beef, poultry, eggs, fish, seafood, asparagus, potatoes, legumes, nuts, seeds, soy and whole grains. Foods low in asparagine include most fruits and vegetables.

“Our study adds to a growing body of evidence that suggests diet can influence the course of the disease,” said Simon Knott, PhD, associate director of the Center for Bioinformatics and Functional Genomics at Cedars-Sinai and one of two first authors of the study. The research was conducted at more than a dozen institutions.

If further research confirms the findings in human cells, limiting the amount of asparagine cancer patients ingest could be a potential strategy to augment existing therapies and to prevent the spread of breast cancer, Knott added.

The researchers studied triple-negative breast cancer cells, which grow and spread faster than most other types of cancer cells. It is called triple negative because it lacks receptors for the hormones estrogen and progesterone and makes little of a protein called HER2. As a result, it resists common treatments—which target these factors and has a higher-than-average mortality rate.

Research from past studies found that most tumor cells remain in the primary breast site, but a subset of cells leaves the breast and enters the bloodstream. Those cells colonize in the lungs, brain and liver, where they proliferate. The study team wanted to understand the particular traits of the tumor cells circulating in the blood and in the sites where the cancer has spread.

The researchers discovered that the appearance of asparagine synthetase—the enzyme cells used to make asparagine—in a primary tumor was strongly associated with later cancer spread.

The researchers also found that metastasis was greatly limited by reducing asparagine synthetase, treatment with the chemotherapy drug L-asparaginase, or dietary restriction. When the lab mice were given food rich in asparagine, the cancer cells spread more rapidly.

“The study results are extremely suggestive that changes in diet might impact both how an individual responds to primary therapy and their chances of lethal disease spreading later in life,” said the study’s senior author, Gregory J. Hannon, PhD, professor of Cancer Molecular Biology and director, Cancer Research UK Cambridge Institute, University of Cambridge in England.

Investigators now are considering conducting an early-phase clinical trial in which healthy participants would consume a low-asparagine diet. If the diet results in decreased levels of asparagine, the next scientific step would involve a clinical trial with cancer patients. That trial likely would employ dietary restrictions as well as chemotherapy and immunotherapy, Knott said.

Studying the effects of asparagine also could alter treatments for other types of cancer, investigators say.

“This study may have implications not only for breast cancer, but for many metastatic cancers,” said Ravi Thadhani, MD, MPH, vice dean, Research and Graduate Research Education, at Cedars-Sinai.

 Explore further: Researchers identify specific protein that helps breast cancer to spread

More information: Simon R. V. Knott et al, Asparagine bioavailability governs metastasis in a model of breast cancer, Nature (2018). DOI: 10.1038/nature25465

Posted in Breast Cancer - impalpable breast lesions | Leave a Comment »

CRISPR on TED Ideas worth spreading – Ellen Jorgensen

February 8, 2018 by 2012pharmaceutical

CRISPR on TED Ideas worth spreading – Ellen Jorgensen, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

CRISPR on TED Ideas worth spreading – Ellen Jorgensen

Reporter: Aviva Lev-Ari, PhD, RN

On same webpage see other CRISPR Talk on TED on the right hand side of the webpage

 

SOURCE

Posted in CRISPR/Cas9 & Gene Editing | Leave a Comment »

2018 Dan David Prize Laureates announced on 2/7/2018

February 8, 2018 by 2012pharmaceutical

2018 Dan David Prize Laureates announced on 2/7/2018

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #250: 2018 Dan David Prize Laureates announced on 2/7/2018. Published on 2/8/2018

WordCloud Image Produced by Adam Tubman

2018 laureates

 
SOURCES

Posted in Interviews with Scientific Leaders, The Dan David Prize | Leave a Comment »

The median ratio was 140:1 – American CEOs earnings vs their rank-and-file workers

February 6, 2018 by 2012pharmaceutical

The median ratio was 140:1 – American CEOs earnings vs their rank-and-file workers

Reporter: Aviva Lev-Ari, PhD, RN

 

 

What American CEOs earn compared with their rank-and-file workers

By Amy X. Wang

February 5, 2018

Equilar’s survey, which offers one of the first glimpses into the official ratio disclosures rolling out thanks to the 2015 ruling, is still only one sample. Previous calculations for average CEO-to-worker pay ratio in the US have been as high as 372-to-one—and the country’s soaring executive pay growth, especially when compared to that of the rest of the world, has raised eyebrows in recent years. Hence, the SEC’s request for companies to report their CEO’s pay in relation to their workers’ pay. And even getting that (paywall) was a tough fight.

The median ratio was 140:1.

Keep in mind that medians are the middle numbers in a set, not the average. At the 25th percentile, the ratio was 72:1, and it was 246:1 at the 75th percentile—meaning there are even higher gaps than that. The average ratio of CEO to median worker pay, across those 356 companies, was 241:1.

Ratios swung widely depending on a number of factors, including company size, location, and employment sector. Below are the industries with the highest pay gaps between CEOs and rank-and-file workers:

Industry Earnings ratio of CEO to median worker
Retailing 669:1
Food, beverage, tobacco 233:1
Capital goods 175:1
Health care equipment and services 175:1
Materials 141:1
Insurance 139:1

On the other hand, the smallest gaps:

Industry Earnings ratio of CEO to median worker
Technology hardware and equipment 125:1
Software and services 115:1
Banks 95:1
Utilities 78:1
Energy 72:1

SOURCE

https://work.qz.com/1196106/how-much-do-ceos-make-140-times-what-their-median-employee-does/

Posted in Income Disparity | Leave a Comment »

2018 MassBio Annual Meeting March 21, 2017 8:00 AM – March 22, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

February 6, 2018 by 2012pharmaceutical

2018 MassBio Annual Meeting March 21, 2017 8:00 AM – March 22, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

Due to Snow Storm Warning I did not attend

 

Register

Register

Member Rates

$675.00 Biotechnology
$350.00 Academic, Hospitals, & Non-Profit
$675.00 Associates
$350.00 Government

Non-Member Rates

$875.00 Non-Member
$500.00 Non-Profit
$500.00 Government
$250.00 Student

MASSBIO ANNUAL MEETING
Wednesday, March 21 & Thursday, March 22, 2018
Royal Sonesta, Cambridge

2018 MassBio Annual Meeting

– 
Royal Sonesta Boston40 Edwin Land BoulevardCambridge MA US 02142

Venue WebsiteGet Directions

SPEAKERS

  • Andrew Adams, President, Publicis Health Solutions
  • Derek Adams,PhD, Chief Technology & Manufacturing Officer, bluebird bio
  • Dolores Baksh, PhD, Innovation Leader, Cell Therapy Technologies, GE Healthcare
  • Ashvin Bashyam, PhD candidate in the Department of Electrical Engineering & Computer Science, MIT, Co-President, MIT Biotechnology Group
  • Angela Belcher, PhD, James Mason Crafts Professor, Professor of Biological Engineering, Materials Science and Engineering, Koch Institute for Integrative Cancer Research, MIT
  • Maria Berkman, MD, Director, Broadview Ventures
  • Aaron Bernstein, PhD Candidate in Cellular & Molecular Physiology, Tufts University, President, Tufts Biomedical Business Club
  • Kerrie Brady, Chief Business Officer, Centrexion
  • Marta Bralic, Vice President of Business Development, Flatiron Health
  • Caeleigh Brown
  • Jim Burns, PhD, President & CEO, Casebia Therapeutics
  • Abbie Celniker, PhD, Partner, Third Rock Ventures
  • Anna Christo, Senior Director, Science and Technology, Alexandria Real Estate Equities, Inc.
  • George Church, PhD, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology
  • Bob Coughlin, President & CEO, MassBio
  • Agnieszka Czechowicz, MD, PhD, Assistant Professor of Pediatrics (Stem Cell Transplantation), Stanford University
  • Matt Dallas, Chief Financial Officer, AVEO Pharmaceuticals
  • Frank David, MD, PhD, Founder and Managing Director, Pharmagellan
  • Mitch DeKoven, Principal, – Health Economics and Outcomes Research, Real World Insights, IQVIA
  • Oliver Dodd, Co-Founder, Remora Therapeutics
  • Alin Dragos, Digital Currency Initiative Product Management, MIT Media Lab
  • Nick Eliovits, Managing Partner, Olive Tree Capital
  • Jeff Elton, Managing Director and Global Head, Predictive Health Intelligence, Accenture
  • Giovanna Fessenden, Of Counsel, Hamilton Brook Smith Reynolds
  • Naomi Fried, PhD, Founder and CEO, Health Innovation Strategies
  • Stephen Galebach, Galebach Law
  • Brian Gallagher, Partner, SR One
  • Brett Geiger, PhD candidate in the Department of Biological Engineering, MIT, Co-Presidents, MIT Biotech Group
  • Rebecca Gibbs, PhD candidate in Biological and Biomedical Sciences, Harvard University, President, Harvard Biotech Club
  • Michael Gibson, MD, CEO, Baim Institute for Clinical Research
  • David Glass, PhD, D. Glass Associates
  • Laurie Glimcher, MD, President and CEO, Dana-Farber Cancer Institute
  • Marc Goldberg, Managing Director, BioVentures Investors
  • Arjun Goyal, MD, Co-founder and Managing Director, Vida Ventures
  • Aine Hanly, Vice President, Process Development and Massachusetts Site Head, Amgen
  • Peter Hecht, PhD, CEO, Ironwood Pharmaceuticals
  • Martin Heidecker, PhD, Director, Investment Manager, Boehringer Ingelheim Venture Fund
  • Peter Hein, MD, PhD, External Innovation Lead and Director, Innovative Medicines Unit, Grünenthal
  • Arthur Hiller, CEO, Antyllus Therapeutics, Inc., and Principal, Hiller Life Sciences Strategies, LLC
  • Lori Hu, Principal, Vertex Ventures
  • Laura Indolfi, PhD, CEO & Co-Founder, PanTher Therapeutics
  • Matt Kapusta, CEO, uniQure
  • Stephen Kennedy Smith, Principal Park Agency – Kennedy Enterprises
  • Ash Khanna, PhD, Venture Partner, Pivotal bioVenture Partners
  • Daniel Kohane, MD PhD, Boston Children’s Hospital
  • Julie Krop, MD, Chief Medical Officer and Senior Vice President of Clinical Development and Regulatory Affairs, AMAG Pharmaceuticals
  • Robert Langer, ScD, the David H. Koch Institute Professor, MIT
  • Harvey Lodish, PhD, Professor of Biology and Biological Engineering, MIT and Founding Member, Whitehead Institute
  • David Lucchino, Co-Founder, President & CEO, Frequency Therapeutics
  • Larry Lucchino, Boston Red Sox President/CEO Emeritus and Chairman of the Board, Jimmy Fund
  • Anna Maiques, CEO, Neuroelectrics
  • Eddie Martucci, CEO, Akili
  • Frank McGillin, Chief Commercial Officer, NeuroMetrix
  • Terry McGuire, Founding Partner, Polaris Partners
  • Marian McKee, PhD, Senior Director and Head of Global Operational Development Services, MilliporeSigma
  • Lindsay McNair, MD, Chief Medical Officer, WIRB-Copernicus Group
  • Anne Mostue, Anchor, Reporter, Bloomberg News
  • Christopher Murphy, Chief Manufacturing Officer, Brammer Bio
  • Marian Nakada, PhD, Vice President, Venture Investments, Johnson & Johnson Innovation
  • Dana Ono, PhD, Managing Partner, OLS Ventures
  • Lucinda Orsini, Associate Chief Science Officer, International Society For Pharmacoeconomics and Outcomes Research
  • Michio Painter, PhD, Co-Founder and CEO, Blue Therapeutics
  • Maria Palasis, PhD, President & CEO, 480 Biomedical
  • Catherine Parham, Vice President, Clinical Therapeutic Area Head, Shire
  • Leila Pirhaji, PhD, CEO, ReviveMed Technologies
  • Chandra Ramanathan, PhD, Head, East Coast Innovation Center, Bayer
  • Jim Roach, MD, Chief Medical Officer, Pulmatrix
  • Marc Rubenstein, Partner, Ropes & Gray
  • Stephen Sallan, MD, Quick Family Chair, Pediatric Oncology, Dana Farber Cancer Institute
  • Rev. Dr. James Sherblom
  • Al Sokol, Partner, McDermott, Will & Emery
  • Lesley Solomon, Senior Vice President Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
  • Christopher de Souza, PhD, Director, Broadview Ventures
  • Edie Stringfellow, Director of Diversity & Inclusion, MassBio
  • John Tagliamonte, Chief Operation Officer, WntRx and EIR, MassBio Science
  • Barry Ticho MD PhD, Chief Medical Officer, Stoke Therapeutics
  • Praveen Tipirneni, MD, President & CEO, Morphic Therapeutic
  • Ailis Tweed-Kent, MD, CEO, Cocoon Biotech & Attending Physician, Massachusetts General Hospital
  • Stephen Ubl, President & CEO, PhRMA
  • Akshay Vaishnaw, MD, PhD, Executive Vice President of R&D and Chief Medical Officer, Alnylam Pharmaceuticals
  • Francois Valencony, General Manager, Mérieux Développement
  • Ramani Varansai, President & CEO, X-Biotix Therapeutics, Inc.
  • Terry Vance, Chief Business Officer, BioMotiv
  • Alex Waldron, Chief Commercial Officer, Pear Therapeutics
  • Russ Wilcox, Partner, Pillar
  • Susan Windham-Bannister, PhD, President & CEO, Biomedical Growth Strategies
  • Cissy Young, PhD, Managing Director, Russell Reynolds Associates

https://www.massbio.org/events/2018-massbio-annual-meeting-2487?tab=speakers

Day 1

Welcome

Plenary
8:30 am – 9:00 am

Keynote Address

Plenary
9:00 am – 9:30 am

Jimmy Fund & Dana Farber Cancer Institute: 70 Years of Helping Patients

Plenary
9:30 am – 10:15 am

Networking Break

10:15 am – 10:30 am

Diversity in Leadership

Business
10:30 am – 11:15 am

The Changing Role of Chief Medical Officers

Science
10:30 am – 11:15

Getting to Better Pain Relief

Emerging Priorities
10:30 am – 11:15 pm

A Candid Conversation with Steve Ubl of PhRMA and Bob Coughlin of MassBio

Plenary
11:15 am – 12:00 pm

Lunch

12:00 pm – 12:15 pm

Presentation of the 2018 Innovative Leadership Award to Jeffrey Leiden, MD PhD, Chairman, President & CEO, Vertex Pharmaceuticals

Plenary
12:15 pm – 12:45pm

Fireside Chat: Life Lessons in the Life Sciences

Plenary
12:45 pm – 1:30 pm

Rock Stars of Life Sciences

Plenary
1:30 pm – 2:30 pm

Networking Break

2:30 pm – 3:00 pm

Tenacity, Perseverance, Pivots, and Courage in Biotech

Business
3:00 pm – 3:45 pm

Addressing the Complexities in Gene Therapy and Regenerative Technologies

Science
3:00 pm – 3:45 pm

Bitcoin, ICOs and Blockchain in Life Sciences: Hype or Hope?

Emerging Priorities
3:00 pm – 3:45 pm

The Nature of Real Data in Health Economics

Business
3:45 pm – 4:30 pm

Tackling the Intractable: Future of Cardiovascular Diseases

Science
3:45 pm – 4:30 pm

Physicians and Clinicians Speak About Drugs

Emerging Priorities
3:45 pm – 4:30 pm

World Series Reception featuring the 2007 & 2012 Trophies and an Appearance from Wally the Green Monster

4:30 pm – 6:00 pm

Day 2

Breakfast

8:30 am – 9:00 am

MassBio Founders Discuss the Industry: 1985 to Today

Plenary
9:00 am – 9:45 am

Venture Capitalist Speak About the Future of Deal Making

Business
9:45 am – 10:45 am

Digital Therapeutics

Science
9:45 am – 10:45 am

MassCONNECT: What I Learned

Emerging Priorities
9:45 am – 10:45 am

Networking Break

10:45 am – 11:15 am

BioPharma Investor Funds: How Are They Different?

Business
11:15 am – 12:00 pm

University Biotech Clubs: Their Mission and Vital Role in the Ecosystem

Science
11:15 am – 12:00 pm

Family Office

Emerging Priorities
11:15 am – 12:00 pm

Lunch

12:00 pm – 12:20 pm

Mayor Martin J. Walsh, City of Boston

Plenary
12:30 pm – 12:35 pm

Innovative School of the Year Award to Essex Technical High School

Plenary
12:35 pm – 1:00 pm

Keynote Address

Plenary
12:45 pm – 1:30 pm

Networking Dessert Reception

1:30 pm – 2:00 pm

 ABOUT

MassBio’s largest event, drawing over 400 industry leaders, the Annual Meeting is a two-day event that focuses on the most timely and critical challenges facing the Massachusetts biopharma industry.

From breakthroughs in scientific endeavors to startups and new business ventures, the Annual Meeting will cover the most innovative advancements in the industry, presented in new and interactive formats. It will recognize and award industry leaders, provide ample networking opportunities, and showcase Massachusetts as the leader in the biopharma industry worldwide.

This year, we’ll have conference-wide sessions, keynotes and three breakout tracks: Business, Science and Emerging Priorities.

Highlights include:

  • Fireside chat with Robert Langer and Terry McGuire: Life Lessons in the Life Sciences.

Topics to be discussed include:

  • Diversity in Leadership
  • Health Economics
  • Venture Capital: traditional, corporate and family offices
  • Tenacity in Biotechnology
  • Regenerative Technologies
  • Opioids
  • Digital Currency
  • Physicians and Clinicians
  • and more.

 

For sponsorship opportunities, contact Elizabeth Steele.

 Signature Events,

SOURCE

https://www.massbio.org/events/2018-massbio-annual-meeting-2487

Posted in Conference Coverage with Social Media | Leave a Comment »

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

February 5, 2018 by 2012pharmaceutical

Juno acquired by Celgene for $9Billion following Gilead acquisition of Kite Pharma for 12.9 Billion

Reporter: Aviva Lev-Ari, PhD, RN

 

UPDATED on 2/5/2018

Hans Bishop gets a $287M payday as Juno execs see windfall fortunes — with a $922M payoff for Arch

by john carroll — on February 5, 2018 05:47 AM EST
Updated: 05:48 AM

https://endpts.com/hans-bishop-gets-a-287m-payday-as-juno-execs-see-windfall-fortunes-with-a-922m-payoff-for-arch/?utm_medium=email&utm_campaign=Monday%20February%205%202018&utm_content=Monday%20February%205%202018+CID_aecea465e79bcafc58b92d3615dfacda&utm_source=ENDPOINTS%20emails&utm_term=Hans%20Bishop%20gets%20a%20287M%20payday%20as%20Juno%20execs%20see%20windfall%20fortunes%20%20with%20a%20922M%20payoff%20for%20Arch

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

 john carroll — on February 5, 2018 05:50 AM EST

https://endpts.com/anatomy-of-a-9b-buyout-celgenes-quick-turn-from-junos-close-collaborator-to-new-owner/?utm_medium=email&utm_campaign=Monday%20February%205%202018&utm_content=Monday%20February%205%202018+CID_aecea465e79bcafc58b92d3615dfacda&utm_source=ENDPOINTS%20emails&utm_term=Anatomy%20of%20a%209B%20buyout%20Celgenes%20quick%20turn%20from%20Junos%20close%20collaborator%20to%20new%20owner

 

Other related articles on JUNO published in this Open Access Online Scientific Journal include the following:

Anatomy of a $9B buyout: Celgene’s quick turn from Juno’s close collaborator to new owner

https://pharmaceuticalintelligence.com/2018/02/05/anatomy-of-a-9b-buyout-celgenes-quick-turn-from-junos-close-collaborator-to-new-owner/

Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial AND Acquires privately held Boston, MA-based RedoxTherapies

https://pharmaceuticalintelligence.com/2016/07/14/juno-therapeutics-to-resume-jcar015-phase-ii-rocket-trial-and-acquires-privately-held-boston-ma-based-redoxtherapies/

What does this mean for Immunotherapy? FDA put a temporary hold on Juno’s JCAR015, Three Death of Celebral Edema in CAR-T Clinical Trial and Kite Pharma announced Phase II portion of its CAR-T ZUMA-1 trial

https://pharmaceuticalintelligence.com/2016/07/09/what-does-this-mean-for-immunotherapy-fda-put-a-temporary-hold-on-jcar015-three-death-of-celebral-edema-in-car-t-clinical-trial-and-kite-pharma-announced-phase-ii-portion-of-its-car-t-zuma-1-trial/

Juno Acquires AbVitro for $125M: high-throughput and single-cell sequencing capabilities for Immune-Oncology Drug Discovery

https://pharmaceuticalintelligence.com/2016/01/12/juno-acquires-abvitro-for-125m-high-throughput-and-single-cell-sequencing-capabilities-for-immune-oncology-drug-discovery/

Juno’s approach eradicated cancer cells in 10 of 12 leukemia patients, indicating potential to transform the standard of care in oncology

https://pharmaceuticalintelligence.com/2014/01/14/junos-approach-eradicated-cancer-cells-in-10-of-12-leukemia-patients-indicating-potential-to-transform-the-standard-of-care-in-oncology/

 

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

 

 

 

Posted in Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, CAR-T, Immuno-Oncology & Genomics, Immunotherapy | Leave a Comment »

CRISPR snips a strand of DNA – Visualization of the Process

February 4, 2018 by 2012pharmaceutical

CRISPR snips a strand of DNA – Visualization of the Process, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

CRISPR snips a strand of DNA – Visualization of the Process

Reporter: Aviva Lev-Ari, PhD, RN

 

Watch what it actually looks like when CRISPR snips a strand of DNA

Posted  by 
WATCH VIDEO

Molecular animations are an essential way to demystify and explain complex biological systems. Through the use of stunning imagery and attention to detail, Visual Science and Skoltech have captured the dynamic mechanisms of CRISPR-Cas proteins and their use as research tools.

— Jennifer Doudna, Professor of the Depts. of Molecular and Cell Biology and Chemistry at the UC Berkeley, Executive Director of the Innovative Genomics Institute

You can watch the animation, created by biologists at Russia’s Skoltech Institute and the Visual Science organization, below or at the latter’s website:
SOURCE

Posted in CRISPR/Cas9 & Gene Editing | Leave a Comment »

In 2017, FDA approved a record number of 19 personalized medicines — 16 new molecular entities and 3 gene therapies – PMC’s annual analysis, titled Personalized Medicine at FDA: 2017 Progress Report

January 30, 2018 by 2012pharmaceutical

In 2017, FDA approved a record number of 19 personalized medicines — 16 new molecular entities and 3 gene therapies – PMC’s annual analysis, titled Personalized Medicine at FDA: 2017 Progress Report

Reporter: Aviva Lev-Ari, PhD, RN

 

 

Contact: Christopher J. Wells

Personalized Medicine Coalition

cwells@personalizedmedicinecoalition.org

202-580-9780

FOR IMMEDIATE RELEASE

 

FDA Approves Record Number of Personalized Medicines, Spearheads Six Regulatory Precedents in Field in 2017

Personalized Medicines Now Account for More Than One in Four New Drug Approvals

WASHINGTON (January 30, 2018) — The Personalized Medicine Coalition (PMC) today released a report documenting the record number of new personalized medicines the U.S. Food and Drug Administration (FDA) approved last year, making 2017 the fourth consecutive year that personalized medicines accounted for more than 20 percent of all new drug approvals.

The annual analysis, titled Personalized Medicine at FDA: 2017 Progress Report, shows that FDA approved a record number of 19 personalized medicines — 16 new molecular entities and three gene therapies — in 2017. The report lists a total of six regulatory precedents FDA set last year, as follows:

  1. Record number of 16 personalized medicines approved as new molecular entities
  2. Approval of first three gene therapies
  3. First approval of a tissue agnostic indication for cancer therapy
  4. First authorization for marketing of health-related genetic tests directly to consumers
  5. First approval of a personalized medicine biosimilar
  6. First FDA/CMS joint approval and coverage decision for a next-generation sequencing test

PMC President Edward Abrahams, Ph.D., said the precedents demonstrate how personalized medicine has reshaped drug development in the decade since 2007, when targeted therapies accounted for less than 10 percent of new drug approvals. An influential article published in 2007 in the Harvard Business Review titled “Realizing the Promise of Personalized Medicine,” for example, suggested that FDA was not yet committed to the paradigm. The pharmaceutical industry, the article noted, was at that time hesitant to develop medicines for smaller patient populations, preferring instead to develop “blockbuster” medications that could earn approval for one-size-fits-all applications.

This obviously is no longer true, though there remain many obstacles — notably regarding regulation, reimbursement, access and clinical adoption — that complicate the commercialization of personalized medicine products.

“Despite myriad challenges, the diagnostic and pharmaceutical industries are deeply invested in making health care more effective and efficient by developing products that guide treatments to only those patients who will benefit from them,” Abrahams explained. “As this report shows, FDA is increasingly committed to supporting that effort.”

Laura Koontz, Ph.D., Personalized Medicine Staff Member at FDA, will discuss FDA’s direction in personalized medicine with PMC members during its next Policy Committee Meeting on February 20, 2018.

###

About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information, please visit www.personalizedmedicinecoalition.org.

 

SOURCE

From: Personalized Medicine Coalition <messages@app.production.membersuite.com>

Reply-To: “Christopher Wells (PMC)” <cwells@personalizedmedicinecoalition.org>

Date: Tuesday, January 30, 2018 at 10:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: PMC Report: FDA Approves Record Number of Personalized Medicines, Spearheads Six Regulatory Precedents in Field in 2017

Posted in FDA Regulatory Affairs, Personalized and Precision Medicine & Genomic Research | Leave a Comment »

« Newer Posts - Older Posts »